The Lancet · Online First· Chong-Rui Xu, Yan Zhang, Guinan Lin, Haiyong Wang, Qiming Wang, Dingzhi Huang, Yan Yu, Jin Zhou, Hua Zhong, Lin Wu, Lingxiang Liu, Jianchun Duan, Zhiyi He, Yongzhong Luo, Hongxu Liu, Bi Chen, Xinmin Yu, Feng Xue, Qian Chu, Sanxing Guo, Runxiang Yang, Jia Zhong, Haifeng Liu, Longhua Sun, Xiaorong Dong, Haichuan Su, Peng Zhang, Bin Yang, Sisi He, Yuanyuan Ji, Lixin Wan, Xinghua Han, Jingyu Zhang, Fei Qiu, Lulu Yang, Wei Shi, Yi-Long Wu, HERON-Lung01 Investigators·· 5 小时前AI 评分55
HERON-Lung01 中期分析：ruzaltatug rezetecan 延长 EGFR-TKI 治疗后进展的晚期 EGFR 突变非小细胞肺癌患者 PFS
[Articles] Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China
AI 导读
HERON-Lung01 中期分析显示，ruzaltatug rezetecan 较化疗显著延长 EGFR-TKI 治疗后进展的晚期 EGFR 突变非小细胞肺癌患者无进展生存期（PFS）。这是一项在中国开展的随机、开放标签 III 期临床试验，报告其安全性可管理，支持该药作为这一情境下的潜在治疗选择。当前摘要未提供样本量、随访时间或具体效应量。
来源：The Lancet · Online First · thelancet.com